Smiling woman sitting in front of green wall at AlkermesSmiling woman sitting in front of green wall at AlkermesBlue Triangle graphic

News and Events

Sharing Stories of
Patients, Employees
and Communities

Featured News

October 26, 2021

Alkermes Initiates ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer

Read more

October 25, 2021

Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian ...

Read more

Woman with bun

October 20, 2021

Alkermes to Report Third Quarter 2021 Financial Results on Oct. 27, 2021

Read more

See all press releases

COVID-19 Response 

In response to the urgent and unexpected needs created by the COVID-19 pandemic, Alkermes acted quickly to prioritize the safety of our employees and our communities, and adapted our business practices to support uninterrupted supply of, and patient and provider access to, our marketed and investigational medicines.

Read our response   

Portrait of woman with mask in research laboratory environment

Pandemic Drinking Habits

Alkermes worked with The Harris Poll to conduct a survey exploring drinking patterns during the COVID-19 pandemic and people’s motivations to seek help.  

Learn about the survey

Lessons from Leadership

Senior Director and Research Oncology Program Lead Heather Losey, Ph.D. shares five leadership lessons she’s learned throughout her career as part of an Authority Magazine series highlighting inspirational women in STEM.

Read the article

Portrait of smiling Alkermes employee smiling

Blair Jackson in Alkermes office smiling.

Building for the Future

In a recent interview with Informa Connect's Xconomy, our Chief Operating Officer, Blair Jackson, discusses our ambitions and our evolving strategy in neuroscience and oncology. 

Read the article

Media Resources

Company Description

Alkermes is focused on developing innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction and cancer. As a fully-integrated, global biopharmaceutical company, with U.S. locations in Massachusetts and Ohio, and locations in Dublin and Athlone, Ireland, we apply our scientific expertise and proprietary technologies to develop products designed to make a meaningful difference in the way people manage their diseases. Beyond our scientific pursuits, we also work to help support and enhance the systems through which these complex diseases are treated. We are committed to patient engagement, disease education and supporting policies that enable access to approved treatment options.

Media Inquiries

Email our media team

Company Logos


Company Photo


Corporate Fact Sheet


Follow us on our social channels   

blue triangle graphic

Statements and Positions

The idea that a corporation can play a profoundly positive role in society is central to our vision. It is our obligation to voice our beliefs about issues that impact the patients we serve, the communities in which we live and work and society at large.

Access to Medicines

Read our statement

Marketing Practices

Read our statement

Systemic Racism and Violence

Read our statement

Company Response to COVID-19

Read our response